Tripep's rights offering

Tripep's rights offering

Tripep has finalized a rights offering with a maximum of 48 million units which
fully subscribed would have given Tripep 24 MSEK before transaction costs. The
rights issue has so far raised appr. 16 MSEK. 50.7 % has been subscribed and
paid for using first rights. 3.4 % has been subscribed and paid for without
rights. The rights offering was guaranteed equally between Erik Selin and Rutger
Smith. Rutger Smith had also committed to subscribe for Verazzano Ltds' rights
share comprising approximately 19.8 % corresponding to approximately 4.8 MSEK. 

Rutger Smith has informed Tripep that he owing to a liquidity problem cannot
fulfill his obligation at the moment. Tripep will, however, pursue its demand on
Rutger Smith. In view of the current situation Tripep will bring forward an
already planned private placement in which Tripep's management and people close
to the company intend to participate.

”We receive continuous information from our ongoing phase I/II-study on
ChronVac-C® where now three patients have been included. So far we have not seen
any significant side effects. These are very encouraging study results,
considering that this is one of the major challenges with this type of
treatments. Seen in the light of this and the status of our other projects it is
of course sad that one of our guarantors does not live up to his fulfillment,
however, this does not directly affect any of our ongoing projects”, says
Tripep's CEO Jan Nilsson.



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63, E-mail:
jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail:
anders.vahlne@ki.se


Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB.  For more information, please refer to the
company's Website: www.tripep.se .